Monoclonal antibody therapy for Alzheimer's tracked with PET scans
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with mild cognitive impairment (MCI) due to Alzheimer's or mild-to-moderate Alzheimer's disease.
- You need a positive PIB-PET scan showing amyloid plaques (protein clumps) in the brain.
- Your age must be between 50 and 85.
- You cannot be taking part in any other clinical trial or research study.
- You must not have metal implants or other reasons that would prevent an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This trial tests whether the drug lecanemab works better at different doses for people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to see if the drug can slow memory loss in real-world situations.
This study tests whether a special 3Tesla MRI scan can improve how well antibody treatments work for people with early Alzheimer's disease. The goal is to see if the scan helps make the treatment more effective and safer.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.